Improved outlook on HIV-1 prevention and vaccine development

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 983-994

  Vasan, Sandhya ^a   Michael, Nelson L ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

AIDS; clinical trials; HIV; vaccine

Indexed keywords

AD 26; AD 35; EMTRICITABINE; ERDOSTEINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; NEF PROTEIN; POL PROTEIN; RV 305; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CIRCUMCISION; DISEASE TRANSMISSION; GENITAL ULCER; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUALLY TRANSMITTED DISEASE; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863804436     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.688020     Document Type: Review

References (123)

1. UNAIDS, Report on the Global AIDS Epidemic, 2010
2. Auvert B, Taljaard D, Lagarde E. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: THE ANRS 1265 Trial. PLoS Med 2005;2(11):e298
3. Bailey RC, Moses S, Parker CB. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007;369(9562):643-56
4. Gray RH, Kigozi G, Serwadda D. Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 2007;369(9562):657-66
5. Alanis MC, Lucidi RS. Neonatal circumcision: A review of the world's oldest and most controversial operation. Obstet Gynecol Surv 2004;59(5):379-95
6. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006;20(11):1491-5
7. Patterson BK, Landay A, Siegel JN. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002;161(3):867-73
8. Serour F, Samra Z, Kushel Z, Gorenstein A, Dan M. Comparative periurethral bacteriology of uncircumcised and circumcised males. Genitourin Med 1997;73(4):288-90
9. Johnson KE, Sherman ME, Ssempiija V. Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 2009;23(14):1807-15
10. Price LB, Liu CM, Johnson KE. The effects of circumcision on the penis microbiome. PLoS One 2010;5(1):e8422
11. Dinh MH, Fahrbach KM, Hope TJ. The role of the foreskin in male circumcision: AN evidence-based review. Am J Reprod Immunol 2011;65(3):279-83
12. Wamai RG, Morris BJ, Bailis SA. Male circumcision for HIV prevention: CURRENT evidence and implementation in sub-Saharan Africa. J Int AIDS Soc 2011;14:49
13. Abdool Karim Q, Abdool Karim SS, Frohlich JA. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74
14. Microbicide Trials Network. 2011.Available from: HTTP://www. mtnstopshiv.org/node/3909
15. Grant RM, Lama JR, Anderson PL. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-99
16. USCDC. Available from: HTTP://www. cdc.gov/hiv/prep/pdf/TDF2factsheet.pdf
17. Mujugira A, Baeten JM, Donnell D. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 2011;6(10):e25828
18. Partners Prep Study Team. Pivotal Study Finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. 2011. Available from: HTTP://depts. washington.edu/astda/resources/ PrEP-PressRelease-UW-13Jul2011.pdf.
19. Cohen MS, Chen YQ, McCauley M. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
20. White R, Chileshe M., Dawson L. Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa. Clin Trials 2011;8(1):103-11
21. AVAC. Available from: HTTP://www.avac. org/ht/display/ReleaseDetails/i/ 40672/pid/212
22. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011;25(6):383
23. Katsidzira L, Hakim JG. HIV prevention in Southern Africa: WHY we must reassess our strategies? Trop Med Int Health 2011;16(9):1120-30
24. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: Hiv prevention at a cost? Clin Infect Dis 2011 Dec;53(12):1265-70
25. Michael NL. Oral preexposure prophylaxis for HIV-another arrow in the quiver? N Engl J Med 2010;363(27):2663-5
26. Walker LM, Phogat SK, Chan-Hui PY. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-9
27. Zhou T, Georgiev I, Wu X. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010;329(5993):811-17
28. Song R, Franco D, Kao CY. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol 2010;84(14):6935-42
29. Ho DD. Development of ibalizumab and improved variants for passive immunization. AIDS Vaccin Conf 2011;S04.02
30. Miller CJ, Li Q, Abel K. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005;79(14):9217-27
31. Spira AI, Marx PA, Patterson BK. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183(1):215-25
32. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464(7286):217-23
33. Keele BF, Giorgi EE, Salazar-Gonzalez JF. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105(21):7552-7
34. Salazar-Gonzalez JF, Salazar MG, Keele BF. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206(6):1273-89
35. Li H, Bar KJ, Wang S. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010;6(5):e1000890
36. Bar KJ, Li H, Chamberland A. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010;84(12):6241-7
37. Liu J, Keele BF, Li H. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010;84(19):10406-12
38. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis 1996;23(5):429-40
39. Holmberg SD, Stewart JA, Gerber AR. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988;259(7):1048-50
40. Stamm WE, Handsfield HH, Rompalo AM. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260(10):1429-33
41. Abu-Raddad LJ, Magaret AS, Celum C. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008;3(5):e2230
42. Gaschen B, Taylor J, Yusim K. Diversity considerations in HIV-1 vaccine selection. Science 2002;296(5577):2354-60
43. Letourneau S, Im EJ, Mashishi T Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007;2(10):e984
44. Liao HX, Sutherland LL, Xia SM, Brock ME A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006;353(2):268-82
45. Gao F, Korber BTWeaver E. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004;3(4 Suppl):S161-8
46. Bakari M, Aboud S, Nilsson C. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16(3):319-23
47. Santra S, Liao HX, Zhang R. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16(3):324-8
48. Ndhlovu ZM, Piechocka-Trocha A, Vine S. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 2011;186(12):6914-24
49. Jiang X, Burke V, Totrov M. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 2010;17(8):955-61
50. Almond D, Kimura T, Kong X. Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 2010;26(6):717-23
51. Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009;4(5):431-40
52. Pejchal R, Doores KJ, Walker LM. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011;334(6059):1097- 103
53. Kunert R, Wolbank S, Stiegler G. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004;20(7):755-62
54. Alam SM, McAdams M, Boren D. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007;178(7):4424-35
55. Deeks SG, Schweighardt B, Wrin T. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: EVIDENCE for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006;80(12):6155-64
56. Dhillon AK, Donners H, Pantophlet R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007;81(12):6548-62
57. Doria-Rose NA, Klein RM, Manion MM. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009;83(1):188-99
58. Binley JM, Lybarger EA, Crooks ET. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008;82(23):11651-68
59. Gray ES, Taylor N, Wycuff D. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009;83(17):8925-37
60. Simek MD, Rida W, Priddy FH. Human immunodeficiency virus type 1 elite neutralizers: INDIVIDUALS with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009;83(14):7337-48
61. Sather DN, Armann J, Ching LK. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009;83(2):757-69
62. Mouquet H, Scheid JF, Zoller MJ. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467(7315):591-5
63. Liao HX, Chen X,Munshaw S. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011;208(11):2237-49
64. Haynes BF, Fleming J, St Clair EW. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308(5730):1906-8
65. Matyas GR, Beck Z, Karasavvas N, Alving CR. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009;1788(3):660-5
66. Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci USA 2012;109(3):875-80
67. Plotkin SA, Plotkin SL. The development of vaccines: HOW the past led to the future. Nat Rev Microbiol 2011;9(12):889-93
68. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055-65
69. Vasan S, Schlesinger SJ, Arrode G. T cell immune responses to HIV-1. Front Biosci 2007;12:2330-43
70. Betts MR, Nason MC, West SM. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107(12):4781-9
71. Koup RA, Safrit JT, Cao Y. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68(7):4650-5
72. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68(9):6103-10
73. Schmitz JE, Kuroda MJ, Santra S. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283(5403):857-60
74. Hessell AJ, Poignard P, Hunter M. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15(8):951-4
75. Burton DR, Hessell AJ, Keele BF. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011;108(27):11181-6
76. Watkins JD, Siddappa NB, Lakhashe SK. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011;6(3):e18207
77. Genesca M, Skinner PJ, Hong JJ With minimal systemic T-cell expansion, CD8+T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 2008;82(22):11181-96
78. Lakhashe SK, Wang W, Siddappa NB. Vaccination against heterologous R5 clade C SHIV: PREVENTION of infection and correlates of protection. PLoS One 2011;6(7):e22010
79. Pitisuttithum P, Gilbert P, Gurwith M. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194(12):1661-71
80. Flynn NM, Forthal DN, Harro CD. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654-65
81. Gilbert P, Wang M, Wrin T. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010;202(4):595-605
82. Buchbinder SP, Mehrotra DV, Duerr A. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-93
83. McElrath MJ, De Rosa Sc, Moodie Z. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008;372(9653):1894- 905
84. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: Two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5(5):357-61
85. Thongcharoen P, Suriyanon V, Paris RM. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: Alvac-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAIDID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46(1):48-55
86. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-20
87. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Ad hoc analysis of behavior and time as co-variants of Thai phase III effiacy trial: rv144. Lancet ID 2012
88. Haynes BF, Gilbert PB, McElrath MJ. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-86
89. O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2011
90. Corey L, Nabel GJ, Dieffenbach C. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3(79):79ps13
91. McConkey SJ, Reece WH, Moorthy VS. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9(6):729-35
92. Sandstrom E, Nilsson C, Hejdeman B. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008;198(10):1482-90
93. McCormack S, Stohr W, Barber T. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008;26(25):3162-74
94. Gudmundsdotter L, Nilsson C, Brave A. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009;27(33):4468-74
95. Goepfert PA, Elizaga ML, Sato A. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011;203(5):610-19
96. Bakari M, Aboud S, Nilsson C. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011;29(46):8417-28
97. Ledgerwood JE, Wei CJ, Hu Z. DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11(12):916-24
98. Vaine M, Wang S, Crooks ET. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008;82(15):7369-78
99. Wang Z, Wang SX, Liu SY Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost". Chin Med J (Engl) 2009;122(19):2339-45
100. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010;28(17):2999-3007
101. Wang S, Kennedy JS, West K. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26(31):3947-57
102. Kraynyak KA, Kutzler MA, Cisper NJ. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther 2009;20(10):1143-56
103. Currier JR, Ratto-Kim S, Ngauy V. Cell-mediated immune responses after DNA delivered by either biojector or electroporation and boosted with a heterologous insert recombinant pox virus. AIDS Vaccin Conf 2011;OA01.02
104. Kalams SA, Edupuganti S, Elizaga M. Robust Immunogenicity after HIV DNA Vaccination with IL-12 Plasmid Cytokine Adjuvant Delivered via Electroporation in HIV Uninfected Adults. AIDS Vaccin Conf 2011;P18.25 LB
105. Hirao LA, Wu L, Khan AS. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008;26(25):3112-20
106. Fuller DH, Simpson L, Cole KS. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997;75(4):389-96
107. Wang S, Pal R, Mascola JR. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006;350(1):34-47
108. Churchyard GJ, Morgan C, Adams E. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;6(8):e21225
109. Jaoko W, Karita E, Kayitenkore K. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010;5(9):e12873
110. Vasan S, Hurley A, Schlesinger SJ. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6(5):e19252
111. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: Clinical application. Expert Rev Vaccines 2010;9(5):503-17
112. Hansen SG, Vieville C, Whizin N. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15(3):293-9
113. Hansen SG, Ford JC, Lewis MS. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473(7348):523-7
114. Mourez T, Mesel-Lemoine M, Combredet C. A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Virology 2011;419(2):117-25
115. Dai K, Liu Y, Liu M. Pathogenicity and immunogenicity of recombinant tiantan vaccinia virus with deleted C12L and A53R genes. Vaccine 2008;26(39):5062-71
116. Health, U.S.N.I.o. Available from: Http://www.clinicaltrials.gov
117. Barouch DH, Liu J, Li H. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482(7383):89-93
118. HVTN. 2011.Available from: Http://hvtnews. wordpress.com/2011/09/13/hvtn- 505-expansion-in-response-to-an-evolvingfield
119. Young KR, McBurney SP, Karkhanis LU, Ross TM. Virus-like particles: Designing an effective AIDS vaccine. Methods 2006;40(1):98-117
120. Melchers M, Matthews K, De Vries RP. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 2011;8:48
121. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011;239(1):178-96
122. Li X, Fujio M, Imamura M. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 2010;107(29):13010-15
123. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 2011;140(2):142-51